Roche Suspends German Capital Commitments Over Drug Discount Dispute

Key Facts

1Swiss pharma giant Roche has suspended its capital commitments in Germany due to a dispute over statutory drug rebates.

2CEO Daniel Steiners warned that Berlin's drug rebate policies are shattering trust in the German market.

Swiss pharma giant Roche has suspended its capital commitments in Germany due to a dispute over statutory drug rebates. Benzinga reported that CEO Daniel Steiners warned that Berlin's drug rebate policies are shattering trust in the German market, leading to the halt of new investments.

RHHVF closed at $457.35 on October 16, 2026, amid increasing regulatory headwinds in a major European market. This decision coincides with broader economic shifts in Germany, where wholesale prices rose 8.7% year-on-year as of October 14, 2026, exceeding the forecasted 7%.